GlassScriptPhysician profile
Katayun Irani
NPI 1255422739
$39,708.03
in general payments reported to CMS, 2019-2025
14 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,794 · 2021: $5,894 · 2022: $5,626 · 2023: $325 · 2024: $4,280 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,000 · Travel and Lodging: $1,316 · Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,000.00 |
| Travel and Lodging | $1,316.43 |
| Food and Beverage | $740.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $38,512.04 | 2019-2025 | Da Vinci Surgical System |
| Covidien LP | $689.77 | 2019-2020 | |
| Medtronic, INC. | $241.35 | 2023-2025 | Rapidvac, Signia, V-Loc 180 |
| Medical Device Business Services, INC. | $39.01 | 2025 | Linx Reflux Management System |
| Redhill Biopharma INC. | $38.38 | 2021-2022 | |
| Celgene Corporation | $37.26 | 2022 | |
| Baxter Healthcare | $28.43 | 2021 | |
| Heron Therapeutics, INC. | $26.68 | 2023 | Zynrelef |
| Conmed Corporation | $19.75 | 2023 | Airseal |
| Endo Pharmaceuticals INC. | $18.30 | 2020 | |
| Boston Scientific Corporation | $18.22 | 2020 | |
| Novo Nordisk INC | $13.39 | 2023 | Saxenda, Wegovy |
| Ethicon US, LLC | $12.95 | 2019 | |
| Apollo Endosurgery US INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katayun Irani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.